<?xml version='1.0' encoding='utf-8'?>
<document id="19309762"><sentence text="Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives."><entity charOffset="47-59" id="DDI-PubMed.19309762.s1.e0" text="itraconazole" /><entity charOffset="64-83" id="DDI-PubMed.19309762.s1.e1" text="hydroxyitraconazole" /><pair ddi="false" e1="DDI-PubMed.19309762.s1.e0" e2="DDI-PubMed.19309762.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19309762.s1.e0" e2="DDI-PubMed.19309762.s1.e1" /></sentence><sentence text="Itraconazole represents an important therapeutic option for the treatment of fungal infections"><entity charOffset="0-12" id="DDI-PubMed.19309762.s2.e0" text="Itraconazole" /></sentence><sentence text=" Itraconazole undergoes rapid metabolism to form hydroxyitraconazole, which also contributes to the anti-fungal activity exhibited by the parent compound"><entity charOffset="1-13" id="DDI-PubMed.19309762.s3.e0" text="Itraconazole" /><entity charOffset="49-68" id="DDI-PubMed.19309762.s3.e1" text="hydroxyitraconazole" /><pair ddi="false" e1="DDI-PubMed.19309762.s3.e0" e2="DDI-PubMed.19309762.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19309762.s3.e0" e2="DDI-PubMed.19309762.s3.e1" /></sentence><sentence text=" Since both itraconazole and hydroxyitraconazole are effective inhibitors of cytochrome P450 (CYP) 3A4 and p-glycoprotein (pgp)-mediated efflux transporters, they have the potential to elicit drug-drug interaction with a number of CYP3A4 and/or pgp substrates"><entity charOffset="12-24" id="DDI-PubMed.19309762.s4.e0" text="itraconazole" /><entity charOffset="29-48" id="DDI-PubMed.19309762.s4.e1" text="hydroxyitraconazole" /><pair ddi="false" e1="DDI-PubMed.19309762.s4.e0" e2="DDI-PubMed.19309762.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19309762.s4.e0" e2="DDI-PubMed.19309762.s4.e1" /></sentence><sentence text=" This review focuses on providing comprehensive details on the bioanalytical methods available for the quantitation of both itraconazole and hydroxyitraconazole"><entity charOffset="124-136" id="DDI-PubMed.19309762.s5.e0" text="itraconazole" /><entity charOffset="141-160" id="DDI-PubMed.19309762.s5.e1" text="hydroxyitraconazole" /><pair ddi="false" e1="DDI-PubMed.19309762.s5.e0" e2="DDI-PubMed.19309762.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19309762.s5.e0" e2="DDI-PubMed.19309762.s5.e1" /></sentence><sentence text=" Additionally, it provides an overview of the clinical pharmacology (several case studies of drug-drug interactions), pharmacokinetics, pharmacodynamics and metabolism related aspects of itraconazole"><entity charOffset="187-199" id="DDI-PubMed.19309762.s6.e0" text="itraconazole" /></sentence><sentence text="" /></document>